Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dynepo Dosing Schedules in Anemia Associated with CKD
NCT00450333Phase 3Terminated
- Sponsor
- Takeda
- Start
- Oct 2006
- Primary completion
- Jul 2008
- Modality
- Cytokines & Interferons
- Countries
- 7
01
Overview
Phase 3, randomised, open-label trial of epoetin delta in anemia (4 arms), sponsored by Takeda. Primary endpoint: Change From Baseline in Hemoglobin Concentration at 24 weeks. Started Oct 2006; status: terminated.
02
Drugs
epoetin delta
03
Conditions
anemia
Beyond the preview
Go deeper on NCT00450333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00450333.